products

Thoracent

Minimally invasive devices for managing pleural effusions, restoring airway patency, and improving quality of life, along with an expanded suite of GI tools.

Learn more about Thoracent

Diagnostics

Developing molecular diagnostics to triage patients and ensure they get fast and effective care when they need it.

Learn more about Diagnostics

Biopsy Tools

Developing a suite of steerable endobronchial instruments to target difficult-to-reach off-airway nodules.

Learn more about our Biopsy Tools
View all product lines
>>
team

Leadership

Maverix leadership combines decades of clinical, technical, and operating experience.

Learn more about our leadership

Advisors

The Maverix Medical Advisory Board is comprised of leading pulmonary physicians.

Meet our advisors

Partners

Maverix collaborates with firms that are transforming medtech innovation.

See our partners
Meet the whole team
>>
news
Most Recent Article
Fierce Biotech
March 29, 2024

Lung Cancer Startup Maverix Medical Snaps Up Diagnostic Developer Cirrus Bio

Read More
PR Newswire
March 29, 2024
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Read More
Wall Street Journal
November 30, 2023
Startup Ajax Health Extends Medtech Innovation Model to Hologic
Read More
Read all news
See all the news
>>
Contact
careers
menu
Close

News

Fierce Biotech
March 29, 2024
Lung Cancer Startup Maverix Medical Snaps Up Diagnostic Developer Cirrus Bio
After launching late last year, the lung cancer-focused startup Maverix Medical is reaching for the sky with the acquisition of diagnostic developer Cirrus Bio. The Menlo Park, California-based Maverix said the purchase will establish a new testing division aimed at developing a multiomic catalog spanning lung cancer screening through disease management.
Read More
PR Newswire
March 29, 2024
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer

MENLO PARK, Calif., March 29, 2024 /PRNewswire/ -- Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount. Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role...

Read More
Wall Street Journal
November 30, 2023
Startup Ajax Health Extends Medtech Innovation Model to Hologic

Startup Ajax Health’s model for spurring corporate innovation is gaining traction with investors and large medical-technology companies. Menlo Park, Calif.-based Ajax creates turnkey innovation platforms for commercial-stage medtech players, and it has teamed with investment firm KKR and medtech company Hologic to launch...

Read More
Business Wire
November 30, 2023
KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation

NEW YORK & MARLBOROUGH, Mass.--(BUSINESS WIRE)--KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator. The new platform, named Maverix Medical, will be managed by Ajax Health under...

Read More
Journal of Respiration
March 30, 2023
Bronchoscopic Evaluation of a Steerable Needle for Simulated Tumor Targets in the Lung Periphery: A Feasibility Study (Bullseye)

Peripheral bronchoscopy is often performed to biopsy peripheral pulmonary lesions. Despite technological advancements to improve reach and access to the lung periphery, the diagnostic yield of peripheral bronchoscopy has been inconsistent, and challenging, particularly for lesions that are adjacent to peripheral bronchi. Current biopsy instruments are reliant on the catheter or scope to...

Read More
CHEST Journal
October 1, 2021
Initial Experience With Steerable Instrumentation in Human Cadaveric Models with Simulated Tumor Targets

Despite growing experience using advanced guided techniques, the diagnostic yield of bronchoscopy for peripheral pulmonary lesions remains suboptimal, particularly for lesions which are adjacent to peripheral bronchi. While recent publications have focused on improving bronchoscopic reach, access and precision in the lung periphery, few have addressed significant modifications to the...

Read More

Copyright © Maverix

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

textAlign-center
textAlign-left
textAlign-right
text-allcaps
text-italic
textSize-xxs
textSize-xs
textSize-s
textSize-m
textColor-white
textColor-midnight
textColor-cyan
textColor-blue
textSize-L
textSize-xL
textSize-xxL
textSize-xxxL
bgColor-midnight
bgColor-darkblue
bgColor-teal
bgColor-blue
bgColor-cyan
bgColor-lightblue
bgColor-white
bgColor-off-white
bgColor-dark-off-white